Typhoid vaccines ready for implementation

New England Journal of Medicine

Volumn 361, Issue 4, 2009, Pages 403-405

  Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; TYPHOID VACCINE;

CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EDITORIAL; EPIDEMIC; FOOD CONTAMINATION; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MALAISE; MORBIDITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SALMONELLA ENTERICA; SINGLE DRUG DOSE; TYPHOID FEVER; VACCINATION; WATER CONTAMINATION;

EID: 67651159078     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0905519     Document Type: Editorial

References (12)

1. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989;11:Suppl 3:S552-S567.
2. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet 1999;354:734-7.
3. Brooks WA, Hossain A, Goswami D, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005;11:326-9.
4. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009;361:335-44.
5. Ochiai RL, Acosta CJ, Agtini M, et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin Infect Dis 2007;45:Suppl 1:S34-S38.
6. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989;159:766-9.
7. Levine MM, Ferreccio C, Black RE, Lagos R, Martin OS, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 2007;45:Suppl 1:S24-S28.
8. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055-9.
9. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med 1987;317:1101-4.
10. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996;14:435-8.
11. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999;17:Suppl 2:S22-S27.
12. Michel R, Garnotel E, Spiegel A, Morillon M, Saliou P, Boutin JP. Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast. Eur J Epidemiol 2005;20:635-42.